Blue Jet Healthcare Ltd Q1 FY27 Earnings Analysis

- PI vertical expected to be resilient with both top-line and margin sustainability; volume growth and new launches anticipated in FY27. - Contrast media business forecasted to deliver double-digit growth in FY27 supported by volume growth and new product launches (both iodinated and gadolinium types). - Inventory destocking in PI segment completed, leading to improved order visibility and confidence in surpassing previous peak sales of FY25. - Two high-conviction lateral entry opportunities being planned with dedicated capacity at Vizag, expected to scale in 24-30 months. - Peptide building blocks for GLP-1 programs progressing with pilot/lab supplies started; peptide end product stage in early phases. - Artificial sweetener product under validation; commercial volumes expected post-Vizag facility commissioning. - FY27 to see increased participation in innovator-led programs with 3-4 new contrast media product launches. - Overall, strong growth outlook driven by volume increases, new product launches, and capacity expansion.

- Blue Jet Healthcare expects growth driven by improved order visibility in Pharmaceutical Intermediates (PI) and Contrast Media (CM) segments in FY27. - Contrast Media segment shows strong momentum with 3-4 new product launches planned in FY27, aiding double-digit growth. - Pharmaceutical Intermediates/API segment growth to normalize post inventory destocking, poised to cross FY25 levels, supported by new product launches (including peptides and lateral entries) over the medium term. - New lateral entry products have high conviction and dedicated capacity being planned at Vizag, expected to come online in 24-30 months. - Margins expected to be sustained or improve with ongoing vertical integration (Mahad facility) providing supply chain control and reduced pricing volatility. - Long-term growth supported by Vizag greenfield expansion and enhanced R&D investments starting H2 FY27. - Management indicates cautious optimism with FY26 foundational for doubling capacity and chemistry platforms. - Earnings impact expected to become clearer post Q1 FY27 as cost structures and new launches ramp up.

- **Vizag Greenfield Project**: Planned total capex of approximately INR 1,000 crores over about 3 years. Phase 1 to develop dedicated manufacturing blocks for contrast media intermediates, high-intensity sweeteners, and pharma intermediates. - **Mahad Unit 3 Backward Integration Project**: Final stages of completion; expected to start production in H2 FY27. Focused on key raw material for contrast media to strengthen supply chain and resilience. - **Other Additions**: Capex of approximately INR 400 crores proposed in FY27 for Vizag, Mahad completion, and Ambernath expansions. - **Hyderabad R&D Center**: Planned investment of about INR 40 crores to focus on new chemistry platforms including peptides, GLP-1 linked opportunities, and biocatalysts. - **Strategic Capacity Expansion**: Accelerating capex plans supported by strong liquidity; company is currently debt-free.

- The company is currently well-positioned as a debt-free entity with strong liquidity. - There are no immediate plans confirmed for fundraising through debt or equity. - The situation regarding fundraising, especially related to the Vizag investment, is dynamic. - The management will provide updates on any fundraise plans in the coming quarters. - Currently, Blue Jet Healthcare is accelerating its capital expenditure (capex) plans without needing external funding.

- The company has confirmed having orders in hand, especially in the pharma intermediates (PI) segment, with destocking largely completed and shipments rolling out. (Page 16) - Subsequent to supply chain realignment, additional orders have been secured in the PI segment, boosting confidence in near-term volumes. (Page 14) - For contrast media, the increase in revenue to INR190 crores in Q4 belongs entirely to the order book for that quarter, with normalized goods in transit. (Page 14) - Approximately 20 active RFPs (Request for Proposals) are being tracked in the PI and CDMO segment, mainly in chronic therapeutic areas, including GLP-1 programs and peptide building blocks. (Page 5) - Two of these opportunities are expected to move into commercialization during the current year, while two high-conviction commercial-stage lateral opportunities are also under evaluation with dedicated capacity planned at Vizag. (Pages 5, 13)